Feline Calicivirus antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Feline Calicivirus antibodies pairs and antigen for animal health (animal Cat/Feline infectious disease respiratory infection) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Companion Animal disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P021-Ag01	Recombinant Feline Calicivirus protein	$3090.00
GMP-VT-P021-Ab01	Anti-Feline Calicivirus mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P021-Ab02	Anti-Feline Calicivirus mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P021-Ag01
Product Name	Recombinant Feline Calicivirus protein
Pathogen	Feline Calicivirus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Feline Calicivirus antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Feline Calicivirus level test of animal Cat/Feline infectious disease with respiratory infection.
Tag	His
Product description	Recombinant Feline Calicivirus proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P021-Ab01,GMP-VT-P021-Ab02
Pathogen	Feline Calicivirus
Product Name	Anti-Feline Calicivirus mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Feline Calicivirus antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Feline Calicivirus antibodies in Feline Calicivirus level test of animal Cat/Feline infectious disease with respiratory infection.
Product description	Anti-Feline Calicivirus mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Feline Calicivirus antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

Feline calicivirus (FCV) is a highly infectious virus that affects domestic and wild cats, causing a range of respiratory and oral diseases. The virus belongs to the family Caliciviridae, which also includes human noroviruses and sapoviruses that cause gastroenteritis in humans. FCV has a small, non-enveloped, icosahedral structure, with a single-stranded, positive-sense RNA genome that encodes for structural and non-structural proteins. The virus is primarily transmitted through direct or indirect contact with infected cats or their secretions.

FCV infections in cats can manifest in various clinical signs, including fever, sneezing, nasal discharge, oral ulcers, conjunctivitis, and lameness. Cats infected with FCV may develop a mild or severe form of the disease, depending on the strain of the virus and the host immune status. Mild forms of FCV infection often result in self-limiting upper respiratory tract disease, while severe forms can progress to systemic manifestations and pneumonia, leading to morbidity and mortality.

The key determinant of FCV pathogenicity is the capsid protein, which interacts with the host cell receptors and determines tissue tropism and host range. The capsid protein has two domains, the shell (S) domain containing the amino terminus and the protruding (P) domain that projects outward from the virion surface. The P domain contains antigenic sites that induce the production of neutralizing antibodies against the virus, and mutations within this domain contribute to viral evasion of host immunity.

Diagnostic methods for FCV include virological, serological, and molecular approaches. Virological diagnosis involves the isolation and culture of the virus from clinical samples, such as nasal swabs, oral swabs, or whole blood. The virus is cultured in feline cell lines, and cytopathic effects are observed to confirm the presence of the virus. Serological diagnosis involves the detection of antibodies against FCV in serum samples using ELISA or indirect fluorescent antibody tests (IFAT). Molecular diagnosis involves the detection of the viral RNA using reverse transcription polymerase chain reaction (RT-PCR) targeting various regions of the genome, including the capsid protein, 3C protease, and non-structural proteins. These diagnostic methods are widely used in veterinary clinics and research laboratories to confirm FCV infections and monitor virus prevalence and evolution.

The control and prevention of FCV infections in cats rely on vaccination, biosecurity measures, and prompt diagnosis and treatment. Commercially available vaccines induce protective immunity against the P domain of the capsid protein and reduce the severity and incidence of FCV infections. Additionally, strict hygiene protocols and isolation of infected cats are essential to prevent the transmission of the virus among feline populations.

In conclusion, FCV is a highly infectious virus that affects cats worldwide, causing a range of respiratory and oral diseases. The virus has a small, non-enveloped structure with an RNA genome that encodes for structural and non-structural proteins. Diagnostic methods include virological, serological, and molecular approaches, and these techniques are used to confirm FCV infections and monitor virus prevalence and evolution. Vaccination, biosecurity measures, and prompt diagnosis and treatment are essential strategies for controlling and preventing FCV infections in cats.

About GDU